Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies

BACKGROUND: The role of re-immunotherapy in advanced non-small cell lung cancer (NSCLC) remains unclear. No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Imakita, Takuma, Fujita, Kohei, Ito, Takanori, Saito, Zentaro, Oi, Issei, Kanai, Osamu, Tachibana, Hiromasa, Sawai, Satoru, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471535/
https://www.ncbi.nlm.nih.gov/pubmed/37653078
http://dx.doi.org/10.1007/s12672-023-00781-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471535/
https://www.ncbi.nlm.nih.gov/pubmed/37653078
http://dx.doi.org/10.1007/s12672-023-00781-5

Ejemplares similares